Phase II, single-arm trial of carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT in multiple myeloma patients relapsed after the 1st ASCT : Phase II, single-arm trial of carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT in multiple myeloma patients relapsed after the 1st ASCT

Medienart:

Klinische Studie

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

WHO International Clinical Trials Registry Platform - (2022) vom: 24. Okt. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: ;Neoplasms
Phase: Phase 2
Recruitment Status: Recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2020-11-27, Last updated: 2022-11-24

ICTRP ID:

KCT0005635
NCT05497102

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO004985753